ArticleACS central science2020
Chrysomycin A Derivatives for the Treatment of Multi-Drug-Resistant Tuberculosis.
Article in ACS central science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 64 citations in OpenAlex.
- Stereoselective synthesis, VCD study and conformational analysis of C-glycosyl isochromans.Scientific reports · 2026Article
- Breaking resistance: strategies for novel antibacterial therapeutic interventions.Molecular biology reports · 2026Review
- Characterization of six bioactive compounds from two soil-derivedResearch in pharmaceutical sciences · 2025Article
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Collective total synthesis of chartreusin derivatives and bioactivity investigations.Chemical science · 2025Article
- Transcriptomic and metabolomic insights into the antimicrobial mechanisms ofFrontiers in plant science · 2025Article
- An Air-Stable, Single-Component Iridium Precatalyst for the Borylation of C-H Bonds on Large to Miniaturized Scales.Journal of the American Chemical Society · 2024Article
- Chrysomycins, Anti-Tuberculosis C-Glycoside Polyketides fromMarine drugs · 2024Article
- Optimization of fermentation conditions and medium components for chrysomycin a production by Streptomyces sp. 891-B6.BMC microbiology · 2024Article
- Synthesis of C3-Tetrahedron letters · 2024Article
- Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.Journal of pharmaceutical analysis · 2024Review
- Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Frontiers in immunology · 2024Article
- Divergent total syntheses of ITHQ-type bis-β-carboline alkaloids by regio-selective formal aza-[4 + 2] cycloaddition and late-stage C-H functionalization.Chemical science · 2023Article
- Ravidomycin Analogs fromJournal of natural products · 2023Article
- Killing ofScience advances · 2023Article
- Artificial intelligence in microbial natural product drug discovery: current and emerging role.Natural product reports · 2022Review
- Comparative Transcriptome Analysis of Two Chrysomycin-Producing Wild-Type and Mutant Strains ofMetabolites · 2022Article
- Polycarcin V induces DNA-damage response and enables the profiling of DNA-binding proteins.National science review · 2022Article
- Recent Advances on Natural Aryl-Molecules (Basel, Switzerland) · 2022Review
- Chrysomycin A Inhibits the Proliferation, Migration and Invasion of U251 and U87-MG Glioblastoma Cells to Exert Its Anti-Cancer Effects.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a life-threatening disease resulting in an estimated 10 million new infections and 1.8 million deaths annually, primarily in underdeveloped countries. The economic burden of TB has been estimated as approximately 12 billion USD annually in direct and indirect costs. Additionally, multi-drug-resistant (MDR) and extreme-drug-resistant (XTR) TB strains resulting in about 250 000 deaths annually are now widespread, increasing pressure on the identification of new anti-TB agents that operate by a novel mechanism of action. Chrysomycin A is a rare C-aryl glycoside first discovered over 60 years ago. In a recent high-throughput screen, we found that chrysomycin A has potent anti-TB activity, with minimum inhibitory concentration (MIC) = 0.4 μg/mL against MDR-TB strains. However, chrysomycin A is obtained in low yields from fermentation of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.